Objectives: The purpose of this study is to compare the changes in the severity of violent and psychotic symptoms before and after antipsychotics long-acting injections in patients with schizophrenia. Methods: From April, 2017 to April, 2022, a retrospective study through medical records review was conducted. Paliperidone or aripiprazole long-acting injections were prescribed among schizophrenic patients who received outpatient and inpatient treatment at the Department of Psychiatry at Chuncheon National Hospital. The demographic and clinical characteristics were investigated, and the hospitalization days before and after treatment, the number of hospitalizations, CGI-S, hostility of PANSS, and hostility/suspicion of BPRS were compared. Results: Both long-acting injections showed a significant decrease in CGI-S.(Paliperidone: t=14.407, p=0.000 / Aripiprazole: t=14.135, p=0.000). Additionally, it was confirmed that the hostility of PANSS in both groups decreased significantly,(Paliperidone: t=21.507, p=0.000 / Aripiprazole: t=11.403, p=0.000); furthermore, it was significantly decreased in Hostility/Suspicion of BPRS.(Paliperiodone: t=18.123, p=0.000 / Aripiprazole: t=14.480, p=0.000). There was no significant difference in the evaluation score before and after treatment for each longacting injection, indicating that there was no difference in the treatment effect between the two groups. Conclusion: In this study, it was expected that the two long-acting injectable antipsychotics would decrease socio-economic burdens, since they reduced the violence of schizophrenic patients, the number of days, and the number of hospitalizations. In the future, antipsychotics long-acting injections should be considered to aid patients and society. Since there are various limitations in this study, further follow-up studies are needed.